June 29, 2016 - Gilead, a ubiquitous genotypic hepatitis C cocktail therapy in the field of hepatitis C, has made a major milestone in the US regulation, Epclusa. FDA has approved Epclusa for the treatment of all 6 genotypes of hepatitis C.

July 9, 2016 - the ubiquitous gene type hepatitis C cocktail therapy (Epclusa) developed by Gilead, the absolute hegemon in the field of hepatitis C, has achieved a major milestone in the United States